CN117462700A - 一种基于有机硒的纳米颗粒及其制备方法与应用 - Google Patents
一种基于有机硒的纳米颗粒及其制备方法与应用 Download PDFInfo
- Publication number
- CN117462700A CN117462700A CN202311320998.9A CN202311320998A CN117462700A CN 117462700 A CN117462700 A CN 117462700A CN 202311320998 A CN202311320998 A CN 202311320998A CN 117462700 A CN117462700 A CN 117462700A
- Authority
- CN
- China
- Prior art keywords
- selenium
- organic selenium
- nano
- nanoparticles
- nano particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 182
- 239000011669 selenium Substances 0.000 title claims abstract description 154
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 119
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- 239000003607 modifier Substances 0.000 claims abstract description 11
- 239000010949 copper Substances 0.000 claims description 59
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 51
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 47
- 229940055619 selenocysteine Drugs 0.000 claims description 47
- 235000016491 selenocysteine Nutrition 0.000 claims description 47
- 229920001525 carrageenan Polymers 0.000 claims description 38
- 239000000679 carrageenan Substances 0.000 claims description 38
- 229940113118 carrageenan Drugs 0.000 claims description 38
- 235000010418 carrageenan Nutrition 0.000 claims description 35
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 35
- 229910052802 copper Inorganic materials 0.000 claims description 31
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 14
- 150000001879 copper Chemical class 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 4
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 3
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002718 selenomethionine Drugs 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 7
- 230000002000 scavenging effect Effects 0.000 abstract description 6
- 239000003381 stabilizer Substances 0.000 abstract description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000005580 one pot reaction Methods 0.000 abstract description 3
- 229940091258 selenium supplement Drugs 0.000 description 99
- ZKZBPNGNEQAJSX-REOHCLBHSA-N L-selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 47
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000010791 quenching Methods 0.000 description 12
- 230000000171 quenching effect Effects 0.000 description 12
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 11
- 229910001431 copper ion Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- IRPLSAGFWHCJIQ-UHFFFAOYSA-N selanylidenecopper Chemical compound [Se]=[Cu] IRPLSAGFWHCJIQ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- JULROCUWKLNBSN-UHFFFAOYSA-N selenocystine Chemical compound OC(=O)C(N)C[Se][Se]CC(N)C(O)=O JULROCUWKLNBSN-UHFFFAOYSA-N 0.000 description 8
- 108010024636 Glutathione Proteins 0.000 description 7
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 150000003346 selenoethers Chemical class 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 5
- -1 but not limited to Substances 0.000 description 5
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000012670 alkaline solution Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- KTLOQXXVQYUCJU-UHFFFAOYSA-N [Cu].[Cu].[Se] Chemical compound [Cu].[Cu].[Se] KTLOQXXVQYUCJU-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 229930182853 L-selenocysteine Natural products 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001889 high-resolution electron micrograph Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000007626 photothermal therapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B19/00—Selenium; Tellurium; Compounds thereof
- C01B19/007—Tellurides or selenides of metals
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/22—Rheological behaviour as dispersion, e.g. viscosity, sedimentation stability
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种基于有机硒的纳米颗粒及其制备方法与应用,所述基于有机硒的纳米颗粒包括Cu2‑xSe纳米颗粒及其表面修饰物,所述Cu2‑xSe纳米颗粒的硒源及表面修饰物为有机硒;其中,0≤x≤1。本发明通过水相“一锅法”一步合成基于有机硒的纳米颗粒,有机硒在作为硒源的同时,也可作为表面稳定剂,在无需添加额外生物相容性分子的条件下,得到具有较好分散性和生物相容性的Cu2‑xSe纳米颗粒,操作简单,易于推广,且产率高。本发明所提供的基于有机硒的纳米颗粒具有较好的抗炎、抗氧化性能,具备清除自由基的能力,可以用于体内外自由基的清除,也可以用于制备抵抗炎症的药物,具有较好的生物医学应用前景。
Description
技术领域
本发明涉及生物医学技术领域,具体涉及一种基于有机硒的纳米颗粒及其制备方法与应用。
背景技术
近年来,Cu2-xSe纳米颗粒(0≤x≤1)引起了广泛关注。其简单的化学式、复杂的晶体结构和可变的组成,使其具有丰富的物理化学性质和广阔应用,如光声成像、光热治疗、光动力治疗、化学动力治疗和免疫治疗。此外,Cu2-xSe纳米颗粒具有可降解性,可释放出有助于维持身体健康的两种重要微量元素:硒元素和铜元素。硒元素是硒代半胱氨酸和谷胱甘肽过氧化物酶的主要成分,参与机体的主要代谢途径,如甲状腺激素代谢、抗氧化防御系统和免疫功能,在抗氧化、减轻炎症、抗癌和免疫调节等方面发挥重要作用。铜作为人体内的微量元素,与各种信号通路和生物学行为密切相关,体内缺乏铜元素会导致Menkes疾病,而铜元素过载会引发肿瘤细胞发生铜死亡,增强抗肿瘤治疗的效果。
目前合成Cu2-xSe纳米颗粒多是以硒酸钠、二氧化硒、硒粉等无机硒作为硒源,且需要利用多种表面修饰物对纳米颗粒进行表面功能化,以有机硒为原料制备的较少。有些有机硒,如具有可食用性质的硒化卡拉胶(CASe),和生物利用度更高的硒代氨基酸(硒代蛋氨酸、硒代半胱氨酸、以及硒代胱氨酸)等具有较高的生物安全性,易被人体吸收,同时还具有抗炎、抗氧化的作用以及手性特征。以有机硒为硒源合成Cu2-xSe纳米颗粒,不仅丰富了Cu2- xSe纳米颗粒的功能,而且提高了Cu2-xSe纳米颗粒的生物利用度和安全性。但是关于有机硒合成Cu2-xSe纳米颗粒的方法极少,因此亟需发展一种以有机硒为硒源合成Cu2-xSe纳米颗粒的方法。
发明内容
为解决上述技术问题,本发明的目的是提供一种基于有机硒的纳米颗粒及其制备方法与应用。本发明以有机硒为硒源和表面稳定剂合成Cu2-xSe纳米颗粒,所得基于有机硒的纳米颗粒自身具有较好的分散性和生物相容性。该制备方法操作简单,易于推广,产率高,合成的基于有机硒的纳米颗粒具有手性以及较好的抗炎、抗氧化性能,具有较好的生物医学应用前景。
本发明通过以下技术方案实现:
本发明的第一个目的在于提供一种基于有机硒的纳米颗粒,所述纳米颗粒包括Cu2-xSe纳米颗粒及其表面修饰物,所述Cu2-xSe纳米颗粒的硒源及表面修饰物为有机硒;其中,0≤x≤1。
本发明提供一种以有机硒为硒源的纳米颗粒,该纳米颗粒包括Cu2-xSe纳米颗粒以及其表面修饰物,所述的表面修饰物为有机硒。由于硒化亚铜的溶度积常数(Ksp)为1.58×10-61,远低于硒酸铜的Ksp(2.1×10-8)和硒化铜的Ksp(7.94×10-49),因此铜离子优先与有机硒中的硒元素形成硒化亚铜纳米颗粒,当加入过量的有机硒时,有机硒在满足形成Cu2- xSe纳米颗粒所需硒元素的同时,其有机结构内的氮原子和氧原子,可以与Cu2-xSe纳米颗粒表面的铜离子进行配位,从而形成稳定的Cu2-xSe纳米颗粒。因此,有机硒在作为硒源的同时,也可作为表面稳定剂使Cu2-xSe纳米颗粒具有较好的分散性和生物相容性。
进一步地,所述有机硒为硒化卡拉胶和/或硒代氨基酸。
进一步地,所述硒化卡拉胶中硒含量为0.3%~10%,优选为3%。
进一步地,所述硒代氨基酸包括但不限于硒代蛋氨酸、硒代胱氨酸、硒代半胱氨酸,其中硒代胱氨酸含硒量更高,优选硒代胱氨酸。
进一步地,所述纳米颗粒与表面修饰物的质量比为1:(0.1~0.8)。
进一步地,所述Cu2-xSe纳米颗粒的粒径为1nm~100nm。
进一步地,以手性硒代氨基酸为硒源制备得到的基于有机硒的纳米颗粒为手性纳米颗粒。
手性纳米材料可能具有相同的物理化学性质,但是鉴于生物系统自身具有手性性质,并且具有高对映体选择性,因此,对映异构体对机体的功能可能会有很大的不同,通过调控纳米材料的手性可以增强它们与生物分子的相互作用以增强治疗效果。
本发明的第二个目的在于提供一种基于有机硒的纳米颗粒的制备方法,包括以下步骤:将铜盐溶液加入有机硒溶液中,搅拌后得到所述基于有机硒的纳米颗粒。
本发明通过水相“一锅法”一步合成基于有机硒的纳米颗粒,在无需添加额外生物相容性分子的条件下,得到具有较好分散性和生物相容性的Cu2-xSe纳米颗粒,并可以通过调控硒铜比(有机硒中的硒元素与铜盐中的铜元素的摩尔比)、反应温度、反应时间等反应参数得到尺寸和性质可调的纳米颗粒,操作简单,易于推广,且产率高。
进一步地,所述有机硒中的硒元素与铜盐中的铜元素的摩尔比为(0.1~10):1,优选2:1。
进一步地,所述搅拌在25~105℃下进行。
进一步地,所述搅拌时间为10min~36h。
进一步地,所述搅拌后还包括将混合溶液进行离心、超滤、纯化的步骤。
进一步地,所述搅拌后还包括加入生物相容性分子的步骤。
进一步地,所述生物相容性分子为牛血清白蛋白、人血清白蛋白、葡聚糖、聚乙二醇、聚乙烯吡咯烷酮和聚乙烯亚胺中的一种或多种。
加入生物相容性分子能够进一步调节基于有机硒的纳米颗粒的两亲性。
进一步地,所述铜盐包括但不限于硫酸铜、氯化铜、硝酸铜。
在具体实施方式中,以硒化卡拉胶为硒源制备纳米颗粒的方法与以硒代氨基酸为硒源制备纳米颗粒的方法并不相同。
进一步地,以硒化卡拉胶为硒源制备纳米颗粒的方法包括以下步骤:将硒化卡拉胶与还原剂溶于水中,加入铜盐与还原剂的混合溶液,搅拌后得到所述基于有机硒的纳米颗粒。
在具体实施方式中,以硒化卡拉胶为硒源制备纳米颗粒的方法包括以下步骤:
(1)将硒化卡拉胶与还原剂溶于水中,室温下搅拌;
(2)向步骤(1)的反应体系中加入铜盐与还原剂的混合溶液,搅拌后离心去除沉淀,取上清液进行超滤纯化,得到所述基于有机硒的纳米颗粒。
进一步地,硒化卡拉胶和铜盐都需经还原剂还原,所述还原剂包括但不限于抗坏血酸、硼氢化钠、谷胱甘肽。
进一步地,在步骤(1)中,所述硒化卡拉胶与还原剂的摩尔比为1:(2~9)。
进一步地,在步骤(1)中,反应需在空气的充分氧化下进行。
进一步地,在步骤(1)中,所述水优选去离子水。
进一步地,在步骤(2)中,所述铜盐与还原剂的摩尔比为(10~1):1。
进一步地,以硒代氨基酸为硒源制备纳米颗粒的方法包括以下步骤:将硒代氨基酸溶解于碱性溶液中,加入铜盐溶液,搅拌后得到所述基于有机硒的纳米颗粒。
在具体实施方式中,以硒代氨基酸为硒源制备纳米颗粒的方法包括以下步骤:
(1)在氮气环境下,将硒代氨基酸溶解于碱性溶液中,加热至25~105℃,搅拌1~120min;
(2)将铜盐溶液加入到步骤(1)的反应体系中,搅拌后将混合溶液离心去除沉淀,取上清液进行超滤纯化,得到所述基于有机硒的纳米颗粒。
进一步地,在步骤(1)中,所述碱性溶液包括但不限于氨水、氢氧化钠溶液。
进一步地,在步骤(1)中,所述硒代胱氨酸中硒元素与碱性溶液的摩尔比为1:(1~100)。
本发明的第三个目的在于提供以上所述基于有机硒的纳米颗粒在制备抗氧化剂中的应用。
本发明所提供的基于有机硒的纳米颗粒具有较好的抗炎、抗氧化性能,具备清除自由基的能力,可以用于体内外自由基的清除,也可以用于制备抵抗炎症的药物,具有较好的生物医学应用前景。
本发明的有益效果:
1.本发明通过水相“一锅法”一步合成基于有机硒的纳米颗粒,有机硒在作为硒源的同时,也可作为表面稳定剂,在无需添加额外生物相容性分子的条件下,得到具有较好分散性和生物相容性的纳米颗粒,操作简单,易于推广,且产率高。
2.本发明所提供的基于有机硒的纳米颗粒具有较好的抗炎、抗氧化性能,具备清除自由基的能力,可以用于体内外自由基的清除,也可以用于制备抵抗炎症的药物,具有较好的生物医学应用前景。
附图说明
图1是本发明实施例1不同硒铜比的基于硒化卡拉胶的纳米颗粒的透射电镜图和高分辨电镜图。
图2是本发明实施例1硒铜比为2:1、不同浓度的基于硒化卡拉胶的纳米颗粒的紫外-可见吸收光谱图。
图3是本发明实施例1硒铜比为2:1的基于硒化卡拉胶的纳米颗粒的水合粒径和表面电势图。
图4是本发明实施例2基于硒代胱氨酸的纳米颗粒的X-射线衍射(XRD)图谱;其中,图4(a)为不同硒铜比的基于硒代胱氨酸的纳米颗粒的X-射线衍射(XRD)图谱,图4(b)为不同温度条件下得到的基于硒代胱氨酸的纳米颗粒的X-射线衍射(XRD)图谱。
图5是本发明实施例2硒铜比为1:0.5、不同反应时间制备的基于硒代胱氨酸的纳米颗粒的紫外-可见吸收光谱图。
图6是本发明实施例2硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的透射电镜图和高分辨电镜图。
图7是本发明实施例2硒铜比为1:0.5、不同浓度的基于硒代胱氨酸的纳米颗粒的紫外-可见吸收光谱图。
图8是本发明实施例2硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的水合粒径和表面电势图。
图9本发明实施例2硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的圆二色谱图和g因子;其中,图9(a)为硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的圆二色谱图,图9(b)为对应的g因子。
图10是本发明实施例3基于不同有机硒的纳米颗粒体外抗氧化能力图;其中,图10(a)为不同硒铜比的基于硒化卡拉胶的纳米颗粒的抗氧化性能图,图10(b)为基于硒化卡拉胶的纳米颗粒不同浓度下的抗氧化能力图,图10(c)为基于硒代胱氨酸的纳米颗粒不同浓度下的抗氧化能力图。
图11是本发明实施例4基于不同硒的纳米颗粒在体外超氧自由基淬灭能力图;其中,图11(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的超氧自由基淬灭能力图,图11(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的超氧自由基淬灭能力图,图11(c)为目前已报道用无机硒为原料合成的Cu2-xSe纳米颗粒不同浓度下的超氧自由基淬灭能力图。
图12是本发明实施例5基于不同有机硒的纳米颗粒的类谷胱甘肽过氧化物酶活性图;其中,图12(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的类谷胱甘肽过氧化物酶活性图,图12(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的类谷胱甘肽过氧化物酶活性图。
图13是本发明实施例6基于不同有机硒的纳米颗粒的细胞毒性检测结果;其中,图13(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的细胞毒性检测结果,图13(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的细胞毒性检测结果。
具体实施方式
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
实施例1基于硒化卡拉胶的纳米颗粒
一种基于硒化卡拉胶的纳米颗粒(CASe-Cu2-xSe),所述纳米颗粒包括Cu2-xSe纳米颗粒及其表面修饰物,所述Cu2-xSe纳米颗粒的硒源及表面修饰物为硒化卡拉胶;其中,0≤x≤1。
实施例1基于硒化卡拉胶的纳米颗粒的制备方法包括以下步骤:
(1)将不同质量的硒化卡拉胶(含硒量3%)和211.34mg抗坏血酸分别完全溶解在5mL去离子水中,室温下搅拌30min;
(2)加入3mL溶有99.9mg五水硫酸铜和281.8mg抗坏血酸的水溶液,室温下搅拌反应24h。然后停止搅拌,以10000rpm离心10min去除尺寸较大的纳米颗粒,用去离子水超滤纯化两遍,得到基于硒化卡拉胶的纳米颗粒,放于4℃保存;
所述硒化卡拉胶中的硒元素与五水硫酸铜溶液中的铜元素的摩尔比分别为0.5:1、1:1、2:1,对应硒化卡拉胶的质量分别为521mg、1042mg、2084mg。
图1为不同硒铜比的基于硒化卡拉胶的纳米颗粒的透射电镜图,插图为高分辨电镜图,从图中可以看出当硒铜比为2:1时,纳米颗粒的分散性更好。
图2为硒铜比为2:1、不同浓度的基于硒化卡拉胶的纳米颗粒的紫外-可见吸收光谱图,基于硒化卡拉胶的纳米颗粒的浓度以纳米颗粒中的铜离子浓度来计量,对纳米颗粒的紫外吸收与铜离子浓度的关系进行拟合得到线性方程(其中x代表铜离子浓度,y代表纳米颗粒在808nm处的紫外吸光度),可知纳米颗粒的紫外吸收与铜离子浓度之间具有较好的线性关系。
图3为硒铜比为2:1的基于硒化卡拉胶的纳米颗粒的水合粒径和表面电势图,从图中可以看出纳米颗粒的水合粒径半峰宽窄,证明纳米颗粒具有较好的分散性和均一性。
实施例2基于硒代胱氨酸的纳米颗粒
一种基于硒代胱氨酸的纳米颗粒(L-Sec-Cu2-xSe),所述纳米颗粒包括Cu2-xSe纳米颗粒及其表面修饰物,所述Cu2-xSe纳米颗粒的硒源及表面修饰物为硒代胱氨酸;其中,0≤x≤1。
实施例2基于硒代胱氨酸的纳米颗粒的制备方法包括以下步骤:
(1)在100mL三口烧瓶中加入50mL去离子水,在氮气保护下向烧瓶中加入4mL 0.5MNaOH溶液和33.42mg硒代胱氨酸,升温至100℃搅拌15min;
(2)加入不同体积99.9mg/mL的五水硫酸铜溶液,搅拌反应3h后冷却至室温,以10000rpm离心10min去除尺寸较大的纳米颗粒,透析过夜,用去离子水超滤纯化一遍,得到基于于硒代胱氨酸的纳米颗粒,放于4℃保存;
所述硒代胱氨酸中的硒元素与五水硫酸铜溶液中的铜元素的摩尔比分别为1:2、1:1.4、1:0.8、1:0.5,对应五水硫酸铜溶液的体积分别为1mL、0.7mL、0.4mL、0.25mL。
图4(a)为不同硒铜比的基于硒代胱氨酸的纳米颗粒的X-射线衍射(XRD)图谱,其中硒铜比为1:0.5的纳米颗粒更为接近Cu2-xSe的标准卡片,优选1:0.5;图4(b)为不同温度条件下得到的基于硒代胱氨酸的纳米颗粒的X-射线衍射(XRD)图谱,其中100℃所得纳米颗粒更为接近Cu2-xSe的标准卡片,优选100℃。
图5为硒铜比为1:0.5、不同反应时间制备的基于硒代胱氨酸的纳米颗粒的紫外-可见吸收光谱图,其中4h与6h紫外较为接近,说明4h后反应基本结束,优选反应4h的纳米颗粒。
图6为硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的透射电镜图,插图为高分辨电镜图片,从图中可以看出纳米颗粒的尺寸较为均一。
图7为硒铜比为1:0.5、不同浓度的基于硒代胱氨酸的纳米颗粒的紫外-可见吸收光谱图,基于硒代胱氨酸的纳米颗粒的浓度以纳米颗粒中的铜离子浓度来计量,对纳米颗粒的紫外吸收与铜离子浓度的关系进行拟合得到线性方程(其中x代表铜离子浓度,y代表纳米颗粒在808nm处的紫外吸光度),可知纳米颗粒的紫外吸收与铜离子浓度之间具有较好的线性关系。
图8为硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的水合粒径和表面电势图,从图中可以看出纳米颗粒的水合粒径半峰宽窄,证明纳米颗粒具有较好的分散性和均一性。
图9(a)为硒铜比为1:0.5的基于硒代胱氨酸的纳米颗粒的圆二色谱图,图9(b)为对应的g因子,说明L-硒代胱氨酸合成的Cu2-xSe纳米颗粒具有一定的手性。
实施例3基于不同有机硒的纳米颗粒的体外抗氧化能力检测
测试方法为:利用抗氧化能力检测试剂盒(ABTS快速法)分别检测基于硒化卡拉胶的纳米颗粒、基于硒代胱氨酸的纳米颗粒的抗氧化性能。
检测结果如图10所示,基于有机硒的纳米颗粒的浓度以纳米颗粒中的铜离子浓度来计量,图10(a)为不同硒铜比的基于硒化卡拉胶的纳米颗粒的抗氧化性能图,从图中可以看出硒铜比为2:1的纳米颗粒的抗氧化性能更优;图10(b)为基于硒化卡拉胶的纳米颗粒不同浓度下的抗氧化能力图;图10(c)为基于硒代胱氨酸的纳米颗粒不同浓度下的抗氧化能力图。利用originPro 2017拟合两种纳米颗粒的抗氧化能力,得到基于硒化卡拉胶的纳米颗粒EC50=1.76μg/mL,基于硒代胱氨酸的纳米颗粒EC50=1.24μg/mL,从图中可以看出基于硒代胱氨酸的纳米颗粒的抗氧化能力更优。
实施例4基于不同硒的纳米颗粒的体外超氧自由基淬灭能力检测
测试方法为:利用SOD活性检测试剂盒(WST-8法)分别检测基于硒化卡拉胶的纳米颗粒、基于硒代胱氨酸的纳米颗粒的超氧自由基淬灭能力。
检测结果如图11所示,图11(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的超氧自由基淬灭能力图;图11(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的超氧自由基淬灭能力图,测试结果表明本发明制得的纳米颗粒具有类SOD酶的活性,可清除超氧自由基,起到降低活性氧的作用,可用于降低机体由活性氧引起的损伤,发挥抗氧化和抗炎的作用。利用originPro 2017拟合两种纳米颗粒的超氧自由基淬灭能力,得到基于硒化卡拉胶的纳米颗粒EC50=31.4μg/mL,基于硒代胱氨酸的纳米颗粒EC50=4.3μg/mL,基于硒代胱氨酸的纳米颗粒的超氧自由基淬灭能力更优,而图11(c)为目前已报道用无机硒为原料合成的Cu2- xSe纳米颗粒(CSPQ)的EC50=30.5μg/mL,且从图中可以看出本发明制备的基于有机硒的纳米颗粒的超氧自由基淬灭能力要强于现有技术用无机硒为原料合成的Cu2-xSe纳米颗粒的超氧自由基淬灭能力。
实施例5基于不同有机硒的纳米颗粒的类谷胱甘肽过氧化物酶活性检测
测试方法为:利用谷胱甘肽过氧化物酶检测试剂盒(NADPH法)分别检测基于硒化卡拉胶的纳米颗粒、基于硒代胱氨酸的纳米颗粒的类谷胱甘肽过氧化物酶活性。
检测结果如图12所示,图12(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的类谷胱甘肽过氧化物酶活性图;图12(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的类谷胱甘肽过氧化物酶活性图,检测结果表明本申请制备得到的基于有机硒的纳米颗粒具有类谷胱甘肽过氧化物酶的性能,可减少自由基产生,具有抗氧化和抗炎的功能。
实施例6基于不同有机硒的纳米颗粒的细胞毒性检测
测试方法为:利用增强型CCK-8试剂检测不同有机硒的纳米颗粒的细胞毒性,将RAW 264.7细胞铺到96孔板中后,分别将基于硒化卡拉胶的纳米颗粒、基于硒代胱氨酸的纳米颗粒以不同浓度与细胞孵育6h后,每孔加入100μL 10%的CCK-8培养基,在培养箱中37℃避光孵育1h后用酶标仪检测450nm处吸光值。
检测结果如图13所示,图13(a)为基于硒化卡拉胶的纳米颗粒不同浓度下的细胞毒性;图13(b)为基于硒代胱氨酸的纳米颗粒不同浓度下的细胞毒性,检测结果表明本申请制备得到的基于有机硒的纳米颗粒具有较好的生物相容性。
综上所述,本发明提出了一种以有机硒为硒源和表面稳定剂的Cu2-xSe纳米颗粒的合成方法,该合成方法简便,廉价,易于重复,所得纳米颗粒具有较好的分散性、生物相容性和抗炎、抗氧化的性能。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (10)
1.一种基于有机硒的纳米颗粒,其特征在于,所述纳米颗粒包括Cu2-xSe纳米颗粒及其表面修饰物,所述Cu2-xSe纳米颗粒的硒源及表面修饰物为有机硒;其中,0≤x≤1。
2.根据权利要求1所述的纳米颗粒,其特征在于,所述有机硒为硒化卡拉胶和/或硒代氨基酸。
3.根据权利要求2所述的纳米颗粒,其特征在于,所述硒代氨基酸为硒代蛋氨酸、硒代胱氨酸、硒代半胱氨酸中的一种或几种。
4.根据权利要求1所述的纳米颗粒,其特征在于,所述纳米颗粒与表面修饰物的质量比为1:(0.1~0.8)。
5.一种根据权利要求1~4任一项所述的基于有机硒的纳米颗粒的制备方法,其特征在于,包括以下步骤:将铜盐溶液加入有机硒溶液中,搅拌后得到所述基于有机硒的纳米颗粒。
6.根据权利要求5所述的制备方法,其特征在于,所述有机硒中的硒元素与铜盐中的铜元素的摩尔比为(0.1~10):1。
7.根据权利要求5所述的制备方法,其特征在于,所述搅拌在25~105℃下进行。
8.根据权利要求5所述的制备方法,其特征在于,所述搅拌后还包括加入生物相容性分子的步骤。
9.根据权利要求8所述的制备方法,其特征在于,所述生物相容性分子为牛血清白蛋白、人血清白蛋白、葡聚糖、聚乙二醇、聚乙烯吡咯烷酮和聚乙烯亚胺中的一种或多种。
10.根据权利要求1~4任一项所述的基于有机硒的纳米颗粒在制备抗氧化剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311320998.9A CN117462700A (zh) | 2023-10-12 | 2023-10-12 | 一种基于有机硒的纳米颗粒及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311320998.9A CN117462700A (zh) | 2023-10-12 | 2023-10-12 | 一种基于有机硒的纳米颗粒及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117462700A true CN117462700A (zh) | 2024-01-30 |
Family
ID=89633947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311320998.9A Pending CN117462700A (zh) | 2023-10-12 | 2023-10-12 | 一种基于有机硒的纳米颗粒及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117462700A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106692970A (zh) * | 2016-12-30 | 2017-05-24 | 国家纳米科学中心 | 一种硒化铋纳米复合材料及其制备方法和应用 |
CN110277308A (zh) * | 2013-07-18 | 2019-09-24 | 纳米技术有限公司 | 硒化铜纳米粒子的制备 |
WO2022084685A1 (en) * | 2020-10-22 | 2022-04-28 | Pharm 2 Farm Limited | Nanoparticles for use in anti pathogenic applications |
-
2023
- 2023-10-12 CN CN202311320998.9A patent/CN117462700A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110277308A (zh) * | 2013-07-18 | 2019-09-24 | 纳米技术有限公司 | 硒化铜纳米粒子的制备 |
CN106692970A (zh) * | 2016-12-30 | 2017-05-24 | 国家纳米科学中心 | 一种硒化铋纳米复合材料及其制备方法和应用 |
WO2022084685A1 (en) * | 2020-10-22 | 2022-04-28 | Pharm 2 Farm Limited | Nanoparticles for use in anti pathogenic applications |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Venkateswarlu et al. | Fungus-derived photoluminescent carbon nanodots for ultrasensitive detection of Hg2+ ions and photoinduced bactericidal activity | |
Yan et al. | Fabrication and stabilization of biocompatible selenium nanoparticles by carboxylic curdlans with various molecular properties | |
Zhang et al. | Development, physicochemical characterization and cytotoxicity of selenium nanoparticles stabilized by beta-lactoglobulin | |
Li et al. | A fluorescence probe based on the nitrogen-doped carbon dots prepared from orange juice for detecting Hg2+ in water | |
CN111467491A (zh) | 铂修饰MOF 2-Pt-FA作为双向增强光动力治疗药物的合成及在肿瘤治疗中的应用 | |
Getachew et al. | ROS generation/scavenging modulation of carbon dots as phototherapeutic candidates and peroxidase mimetics to integrate with polydopamine nanoparticles/GOx towards cooperative cancer therapy | |
Guo et al. | Biocompatibility selenium nanoparticles with an intrinsic oxidase-like activity | |
Yu et al. | A facile and fast synthetic approach to create selenium nanoparticles with diverse shapes and their antioxidation ability | |
CN110680926B (zh) | 一种纳米诊疗剂及其制备方法与应用 | |
Feng et al. | Bioinspired greigite magnetic nanocrystals: chemical synthesis and biomedicine applications | |
CN108998013B (zh) | 一种绿色荧光量子点及其制备方法和铜离子检测应用 | |
Zhang et al. | pH-responsive drug release and real-time fluorescence detection of porous silica nanoparticles | |
Kamnev et al. | Mössbauer spectroscopy in biological and biomedical research | |
CN115919801B (zh) | 一种单宁酸-锌配位的壳聚糖-硒纳米颗粒的制备方法 | |
Yuan et al. | Defect engineering in biomedical sciences | |
Lakshmi et al. | Lanthanum mediated rutin yellow-fluorescent carbon dots as multifaceted sensing probes for the detection of calcium ions in melanoma and plant cells | |
Wu et al. | Nitrogen-doped MoS2 quantum dots: Facile synthesis and application for the assay of hematin in human blood | |
CN110104689B (zh) | 一种中空二氧化锰纳米颗粒及其制备方法 | |
KR101841303B1 (ko) | 콘텍트 렌즈 및 의료 재료의 유지를 위한 액체 형태의 조성물 | |
Hao et al. | The on–off-on fluorescence sensor of hollow carbon dots for detecting Hg2+ and ascorbic acid | |
Molaei | Turmeric-derived gadolinium-doped carbon quantum dots for multifunctional fluorescence imaging and MRI contrast agent | |
Shao et al. | Mn-doped single atom nanozyme composited Au for enhancing enzymatic and photothermal therapy | |
Pang et al. | Immobilized CeO2@ CN heterogenous structures with enhanced dual modal photodynamic/photothermal bacterial inactivation under NIR laser irradiation | |
CN117462700A (zh) | 一种基于有机硒的纳米颗粒及其制备方法与应用 | |
Viegas et al. | Synthesis of hydrophilic Ag 2 Se quantum dots optically optimized by multivariate strategies: an easy one-pot approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |